• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Propel Software Accelerates Adoption of Agentic AI for PLM, QMS & PIM with Early Customers Using Live Data

    10/9/25 9:04:00 AM ET
    $ALGM
    $GH
    Semiconductors
    Technology
    Medical Specialities
    Health Care
    Get the next $ALGM alert in real time by email

    Technology, Medical Device, and Consumer Goods Companies Achieve Business Efficiencies with Propel One Agentic AI Solution

    Propel, creator of the first product value management (PVM) platform to transform how businesses create, sell, and service products, announces Propel One first customer cohort. Combining the power of Propel's unified, intelligent product thread with the security and scalability of Salesforce Agentforce, Propel One's agentic AI enables users to leverage trusted, relevant product data every time for secure, highly-reliable outcomes. Propel will be on site at Dreamforce 2025 to meet with manufacturing clients across high technology, medical device, industrial, and consumer goods industries and discuss its latest technology including Propel One.

    Propel One introduces agentic AI workflows that go beyond simple automation. By combining Propel's intelligent product thread with Salesforce Agentforce, every AI action is governed by enterprise-grade protections, role-based permissions, and context-aware relationships that eliminate hallucinations and ensure precise, business-relevant outcomes. The platform incorporates trusted product data models including items, bill of materials (BOMs), changes, documents, and metadata, with a robust security layer, and advanced role-based permissions to safeguard sensitive information across every record, document, or field.

    "AI is transforming the way product manufacturers operate, and Propel is at the forefront of this evolution, delivering innovative, agentic solutions that support every stage of the product lifecycle. It's AI that doesn't just automate, but anticipates and acts," said Ross Meyercord, CEO of Propel Software. "Propel One was built to streamline workflows and enhance efficiency in product operations. Early use cases are generating excitement as AI flags component replacements from real-time quality and supply chain data, automatically notifying engineers with recommended solutions, triggering change orders, and streamlining approvals across the organization."

    With many customers representing the company's target industries, sample Propel One early adopters and evaluation partners include Allegro MicroSystems (NASDAQ:ALGM), a global leader in power and sensing solutions for motion control and energy-efficient systems; Breg, Inc, a provider of orthopedic bracing and support solutions; and Guardant Health (NASDAQ:GH), a precision oncology company specializing in developing blood-based liquid biopsy cancer tests.

    "At Guardant, we are utilizing Propel One to determine how we can empower employees at every role and skill level within our organization to make smarter decisions, faster," said Matt Pearson, Vice President, Quality System & Risk, Guardant. "With all of our product information available digitally on a single platform we are confident that Propel One is leveraging accurate, data-driven intelligence to optimize responses that will make our business more efficient - a critical success factor for our company."

    Propel One enables users to analyze, monitor, and accelerate processes across the product lifecycle to increase productivity for PLM and QMS-related workflows, including:

    • Product Management: boost product intelligence with AI workflows for item summaries, attachment inquiries, and bulk item creation
    • Change Management/Corrective Action Preventive Action (CAPA)/ Non-Conformance (NCR): speed decision making with AI-powered summaries, attachment inquiries, and assignments for missing or required information
    • Design for Serviceability: analytics connect field cases to product lines for data-driven engineering improvements; deliver answers faster in AI-powered product service documents
    • Document Management: agentic AI streamlines document summaries, inquiries, and description generation
    • Training Management: boost compliance and affirm due diligence with AI-generated quizzes for shop floor, field techs, or service providers

    "The Propel One early adopter program is demonstrating how we can accelerate engineering change order processing," said Jeannie Villalobos, Senior Manager, Quality Systems, Breg. "Streamlining change processes while maintaining proper control and oversight will enable our engineers to focus on more strategic, innovative tasks. We are excited to be working hand-in-hand with Propel to uncover efficiency gains across our organization with its new agentic AI solution."

    If you are attending Dreamforce and would like to learn more about the Propel One solution, click here.

    About Propel Software

    Propel helps product companies grow revenue and increase business value. Our product value management platform connects commercial and product teams to optimize decision making, drive process efficiencies, and engage customers with compelling products and experiences. Propel has a proven track record of improving product quality, speeding time to revenue and profit, and improving customer satisfaction. Recognized as one of America's fastest growing private companies on the Inc. 5000, Propel is a 4x Deloitte Technology Fast 500 winner, and one of Fortune America's Most Innovative Companies. Built on Salesforce, Propel drives product success for hyper growth startups, corporate pioneers, and Fortune 500 leaders in the high tech, medtech and consumer goods industries. For more information, visit propelsoftware.com and follow us on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251009758567/en/

    Media Contact:

    Jessica Mularczyk, [email protected]

    Get the next $ALGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGM
    $GH

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    Guardant Health Inc.
    $GH
    9/22/2025$72.00Overweight
    Wells Fargo
    Allegro MicroSystems Inc.
    $ALGM
    8/1/2025$42.00 → $37.00Buy
    TD Cowen
    Allegro MicroSystems Inc.
    $ALGM
    6/16/2025$38.00Buy
    BofA Securities
    Guardant Health Inc.
    $GH
    4/10/2025$55.00Outperform
    Mizuho
    Guardant Health Inc.
    $GH
    1/23/2025$60.00Overweight
    Barclays
    Allegro MicroSystems Inc.
    $ALGM
    11/22/2024$23.00Overweight
    Wells Fargo
    Allegro MicroSystems Inc.
    $ALGM
    11/12/2024$30.00Buy
    Loop Capital
    More analyst ratings

    $ALGM
    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Saia John G. converted options into 14,167 shares and covered exercise/tax liability with 7,431 shares, increasing direct ownership by 15% to 52,168 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/2/25 8:06:17 PM ET
    $GH
    Medical Specialities
    Health Care

    Chief People Officer Monroe Terilyn J. converted options into 10,477 shares and covered exercise/tax liability with 5,310 shares, increasing direct ownership by 25% to 26,087 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/2/25 8:05:53 PM ET
    $GH
    Medical Specialities
    Health Care

    Chief Information Officer Kalia Kumud converted options into 10,549 shares and covered exercise/tax liability with 5,348 shares, increasing direct ownership by 27% to 24,365 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/2/25 8:05:32 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $ALGM
    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012

    10/9/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Propel Software Accelerates Adoption of Agentic AI for PLM, QMS & PIM with Early Customers Using Live Data

    Technology, Medical Device, and Consumer Goods Companies Achieve Business Efficiencies with Propel One Agentic AI Solution Propel, creator of the first product value management (PVM) platform to transform how businesses create, sell, and service products, announces Propel One first customer cohort. Combining the power of Propel's unified, intelligent product thread with the security and scalability of Salesforce Agentforce, Propel One's agentic AI enables users to leverage trusted, relevant product data every time for secure, highly-reliable outcomes. Propel will be on site at Dreamforce 2025 to meet with manufacturing clients across high technology, medical device, industrial, and consum

    10/9/25 9:04:00 AM ET
    $ALGM
    $GH
    Semiconductors
    Technology
    Medical Specialities
    Health Care

    Allegro MicroSystems to Announce Second Quarter Fiscal Year 2026 Financial Results

    MANCHESTER, N.H., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. (NASDAQ:ALGM) today announced it plans to release financial results for its second quarter fiscal year 2026 prior to the market open on Thursday, October 30, 2025. Following the press release, Mike Doogue, President and Chief Executive Officer, and Derek D'Antilio, Executive Vice President and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time to discuss the Company's results and business outlook. Analysts and investors are invited to join the conference call using the following information: Second Quarter Fiscal Year 2026 Earnings Conference CallDate: Thursday, October 30, 2025Time

    10/9/25 8:00:29 AM ET
    $ALGM
    Semiconductors
    Technology

    $ALGM
    $GH
    SEC Filings

    View All

    $ALGM
    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Guardant Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    9/24/25 7:50:17 AM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 144 filed by Guardant Health Inc.

    144 - Guardant Health, Inc. (0001576280) (Subject)

    9/17/25 4:17:32 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    9/15/25 4:11:12 PM ET
    $GH
    Medical Specialities
    Health Care

    SVP, CTO Doogue Michael covered exercise/tax liability with 2,319 shares and bought $285,000 worth of shares (15,000 units at $19.00), decreasing direct ownership by 4% to 62,404 units (SEC Form 4)

    4 - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Issuer)

    11/19/24 4:16:05 PM ET
    $ALGM
    Semiconductors
    Technology

    President and CEO Nargolwala Vineet A bought $99,446 worth of shares (5,000 units at $19.89), increasing direct ownership by 1% to 356,113 units (SEC Form 4)

    4 - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Issuer)

    11/6/24 4:16:05 PM ET
    $ALGM
    Semiconductors
    Technology

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guardant Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

    9/25/25 8:22:52 AM ET
    $GH
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Guardant Health with a new price target

    Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

    9/22/25 8:30:36 AM ET
    $GH
    Medical Specialities
    Health Care

    TD Cowen reiterated coverage on Allegro Microsystems with a new price target

    TD Cowen reiterated coverage of Allegro Microsystems with a rating of Buy and set a new price target of $37.00 from $42.00 previously

    8/1/25 8:20:32 AM ET
    $ALGM
    Semiconductors
    Technology

    $ALGM
    $GH
    Financials

    Live finance-specific insights

    View All

    Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012

    10/9/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Allegro MicroSystems to Announce Second Quarter Fiscal Year 2026 Financial Results

    MANCHESTER, N.H., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. (NASDAQ:ALGM) today announced it plans to release financial results for its second quarter fiscal year 2026 prior to the market open on Thursday, October 30, 2025. Following the press release, Mike Doogue, President and Chief Executive Officer, and Derek D'Antilio, Executive Vice President and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time to discuss the Company's results and business outlook. Analysts and investors are invited to join the conference call using the following information: Second Quarter Fiscal Year 2026 Earnings Conference CallDate: Thursday, October 30, 2025Time

    10/9/25 8:00:29 AM ET
    $ALGM
    Semiconductors
    Technology

    Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights For the three-month period ended June 30, 2025, as compared to the same period of 2024: Reported total revenue of $232.1 million, an increase of 31%, driven by: Oncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30% Screening revenue of $14.8

    7/30/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allegro MicroSystems Inc.

    SC 13G/A - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Subject)

    11/12/24 1:21:32 PM ET
    $ALGM
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Allegro MicroSystems Inc.

    SC 13G/A - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Subject)

    11/12/24 9:50:12 AM ET
    $ALGM
    Semiconductors
    Technology

    $ALGM
    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Kopin Announces Appointment of Erich Manz as Chief Financial Officer

    Kopin Corporation (NASDAQ:KOPN) a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical products, today announced the appointment of Erich Manz as Chief Financial Officer. Mr. Manz is an accomplished executive, bringing over three decades of financial and accounting experience in sensing, application-specific analog power and semiconductor technology markets. Mr. Manz will replace Rich Sneider, who announced his retirement in May. "We are in the midst of an exciting evolutionary journey at Kopin that can unlock the potential of application-specific optical solutions and high-perform

    8/7/25 4:15:00 PM ET
    $ALGM
    $KOPN
    Semiconductors
    Technology

    Allegro MicroSystems Appoints Rick Madormo as Senior Vice President of Worldwide Sales

    MANCHESTER, N.H., March 12, 2025 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. ("Allegro") (NASDAQ:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy-efficient systems, today announced the appointment of Rick Madormo as Senior Vice President of Worldwide Sales, effective March 24, 2025. Rick will be responsible for leading Allegro's global sales organization and driving revenue growth across automotive and industrial end markets, succeeding Max Glover. Max will transition into an advisory role until his departure on May 16, 2025. "We are thrilled to welcome Rick to Allegro," said Mike Doogue, President and Chief Executive Officer. "His semic

    3/12/25 9:00:42 AM ET
    $ALGM
    Semiconductors
    Technology